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DiagnosticsIn the last decades, molecular biology has moved from gene-by-gene analysis to more complex studies using a
genome-wide scale. Thanks to high-throughput genomic technologies, such as microarrays and next-
generation sequencing, a huge amount of information has been generated, expanding our knowledge on the ge-
netic basis of various diseases. Although some of this information could be transferred to clinical diagnostics, the
technologies available are not suitable for this purpose. In this review, we will discuss the drawbacks associated
with the use of traditional DNAmicroarrays in diagnostics, pointing out emerging platforms that could overcome
these obstacles and offer amore reproducible, qualitative and quantitativemultigenic analysis. Newminiaturized
and automated devices, called Lab-on-Chip, begin to integrate PCR andmicroarray on the same platform, offering
integrated sample-to-result systems. The introduction of this kind of innovative devices may facilitate the tran-
sition of genome-based tests into clinical routine.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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The genomic era startedwith the completion of the HumanGenome
Project in 2001, opening new interesting challenges from biological re-
search to medicine applications. During this period, we have witnessed
the astonishingly fast development of high-throughput technologies,
including hybridization and sequence-based ones, which allowed the
transition from studies involving single genes to those employing a
more extended genomic approach. This is generating a plethora ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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RNA and protein sequences, and OMIM (Online Mendelian Inheritance
in Man) for gene and genetic phenotypes. These public resources,
daily updated, currently contain 46,608 human gene sequences and
4023 phenotypes with a known molecular basis [1–5]. Some of this in-
formation could be already transferred to clinical diagnostics, but the
technologies available are not adequate for this purpose. The actual
challenge is the use of genome-based technologies in clinical practice.
In the next paragraph, we will brieﬂy discuss the two most impor-
tant technologies used in genomic screening analysis.
2. High-throughput technologies in genomics: DNAmicroarrays and
next-generation sequencing
DNA microarrays and next-generation sequencing (NGS) are the
twomost important technologies for high-throughput genomic analysis
[6]. During the past 20 years, DNA microarray technology has been de-
veloped and consolidated as a routine tool in research laboratories and
is now transitioning to the clinic. While we are witnessing this transi-
tion, NGS is catching up [7,8]. Over the past 8 years, a number of NGS
technologies have emerged that enable the sequencing of large
amounts of DNA in parallel and at signiﬁcantly lower costs than conven-
tional methods. NGS technologies are suitable to different applications,
such as whole or targeted genome sequencing, and RNA sequencing
(RNA-seq). Due to cost reduction, the latter application may soon re-
place DNAmicroarrays in transcriptomeproﬁling analysis [9]. However,
the transition of NGS into clinical practice is slowed up by non-
automated experimental procedures and lack of efﬁcient and user-
friendly methods to store, process and analyze the large amount of
data produced [10].
Despite the great potential of traditionalDNAmicroarrays andNGS, a
number of issues need to be tackled to implement these technologies in
clinical diagnostics. In this reviewwewill analyze emerging DNAmicro-
array platforms that may offer immediate opportunities to implement
genomic tests in clinical medicine. Thanks to several characteristics,
these sample-to-result systems are available for real-time detection
and offer a more reproducible, qualitative and quantitative multigenic
analysis.
3. DNA microarray technology: state of the art
DNAmicroarrays technologies are based on the ability of DNA to ﬁnd
and spontaneously bind its complementary sequence in a highly specif-
ic, rapid and reversible manner [11]. Over the years, this technology has
been applied to genome analysis in distinct medical ﬁelds allowing the
association of polygenic alterations to speciﬁc pathologies [12–22]. Ob-
tained DNAmicroarray data are collected in public repositories, such as
Gene Expression Omnibus (GEO), which contains also NGS and other
forms of high-throughput functional genomic data [23]. Although the
collected information could be relevant from a medical perspective,
they are not easily accessible from a clinical practice standpoint and
only few of them have already been transferred to the bed-side.
To date, a small number ofmicroarray-based tests have been cleared
for diagnostics. Themain reason is related to the complexity of this tech-
nology, which is suitable to research laboratories but not to diagnostic
ones. Below we will brieﬂy describe the ﬁrst diagnostic, prognostic or
pharmacogenetic tests based on DNA microarray technology.
TheMammaPrint test by Agendia, the ﬁrst in vitro diagnostic multi-
variate index assay (IVDMIA) to be cleared by theUS Food andDrug Ad-
ministration (FDA) in 2007, is an individualized metastasis risk
assessment test with prognostic value for breast cancer patients with
stage 1 or 2. It analyzes the expression of 70 genes and stratiﬁes patients
into two distinct groups: low risk or high risk of distant recurrence
[19,24–26].
The Pathwork Tissue of Origin Test by Pathwork Diagnostics is a
microarray-based gene expression assay for improving classiﬁcation ofclinicopathologically ambiguous tumors. It can detect the expression
level of 1550 genes in each tumor sample of unknown or poorly differ-
entiated origin (primary or metastatic) and to determine the similarity
to 15 tissue types belonging to known tumors [25,27,28]. This test
gained FDA clearance in 2008 for frozen samples and in 2010 for
formalin-ﬁxed and parafﬁn-embedded samples.
The AmpliChip CYP450 by Roche, cleared by the FDA in 2004, is a
pharmacogenetic test based on Affymetrix microarray technology that
analyzes allelic variations in two highly polymorphic cytochrome
P450 genes (CYP2D6 and CYP2C19), whose encoded enzymes regulate
the metabolism of drugs from a variety of classes. By predicting altered
drugmetabolism, it is possible to prevent harmful drug interactions and
to ensure the optimal use of drugs [25,29–31].
Despite the undeniable advantages of these tests, their applications
in clinical settings are still limited by the use of traditional microarray
technology at few highly specialized laboratories. In the next section,
we will analyze in detail the advantages and limits of traditional micro-
array technology.
4. DNA microarray technology: advantages and limits
Themain beneﬁts of DNAmicroarray technology are high-throughput
analysis,miniaturization and safety [32]. The high-throughput analysis al-
lows parallelism through a direct comparison between thousands of
probes spotted on the microarray and their complementary targets.
This advantage has been reached thanks to miniaturization of the array
surface, leading also to a signiﬁcant improvement in terms of decrease
of reaction volumes, increase of sample concentration and acceleration
of hybridization kinetic. Safety derives from the use of ﬂuorochrome la-
beling methods, which avoid handling by the operator of radioactive
or toxic compounds during the experimental process.
Despite the undisputed advantages of DNA microarray technology,
there are many limiting factors that hinder their routine use in diagnos-
tics. Some of these, such as the lack of accuracy and reproducibility
[33–37], depend on the experimental phases. Although a detailed de-
scription of these limiting factors goes beyond the focus of this review,
we will brieﬂy describe them below.
- Sample preparation and labeling. In this phase, the sample quality and
quantity have a crucial role since its partial or total degradation can
affect the entire experimental outcome.
- Hybridization and post-hybridization washing. The speciﬁc binding
between probes and their complementary targets mainly depends
on the stringency of washing buffers and temperature. Small chang-
es in these phases, which are not fully automated,may produce non-
speciﬁc interactions.
- Image acquisition. Image acquisition can be inﬂuenced by scanning
parameters, such as intensity and signal resolution, which are used
to increase the sensitivity and reduce the noise. The resulting
image has to be further submitted to quality assessment and pre-
processing data analysis steps (such as grid overlay) that could
greatly affect the ﬁnal results.
Another important aspect affecting accuracy and reproducibility of
DNA microarrays is the low dynamic range of detection. Part of the sig-
nals detected by traditional DNAmicroarrays fall in awindowwith a lin-
ear dynamic range, whereas those near to background or saturating
levels are not.
The complexity of traditional DNA microarray resides not only in its
experimental procedures and image acquisition, but also in analysis and
interpretation of obtained data that require dedicated software and bio-
informatics staff. Almost all experimental and analytical phases depend
on the operator, and the lack of automation further reduces accuracy and
reproducibility. Additional limits of traditional DNAmicroarray technol-
ogy include the requirement of highly skilled personnel, high costs, and
prolonged procedures (generally 48 h).
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tant constraints when a microarray test has to be cleared for in vitro
clinical diagnostic use by regulatory authorities [25,26,38,39]. In the
next sections, we will discuss how research and technology progresses
are trying to overcome these limits.
5. New DNA microarray platforms
In order to overcome some of the limiting factors associated to
microarray-based tests in clinical practice, industries are starting to com-
mercialize miniaturized devices, called Lab-on-Chips (LOCs), incorporat-
ing both disposable microelectronic and microﬂuidic components. The
latter allows manipulating the small volume ﬂuids, loading the chip and
ﬁlling the reaction chambers without the risk of bubble formation or
leaks [40–43]. These devices permit the integration of all, or almost all,
experimental phases in a single chip, simplifying the entire analytical pro-
cess and drastically reducing the handling by the operator, thus allowing
the execution of the test in a short time. Additional advantages of LOCs
include decrease of reagent and sample volumes, possibility to integrate
a PCR chamber, rapid analysis, low-cost and minimal risk of sample con-
tamination. The reduction of human error, togetherwith the standardiza-
tion and automation of all process operations, increase accuracy and
reproducibility of the results obtained. Thanks to these characteristics,
some LOCs are evolving towards Point-of-Care (POC) devices, offering
the opportunity to move genome-based analysis to the bed-side. More-
over, POCs can be easily transported to remote locations decreasing the
need of large and specialized diagnostics facilities [40,44,45].
In the next paragraphs, we will discuss four novel DNA microarray
platforms that include an associated or integrated PCR, highlighting
their technical features as indicated by their manufacturers.
5.1. PCR-microarray LOCs
The detection limit of traditional DNAmicroarrays imposes the ampli-
ﬁcation of extracted DNA/RNA. PCR, therefore, is often used for ampliﬁca-
tion and labeling of samples before their hybridization onto traditional
DNA microarrays. In the new devices, PCR is now being integrated, on
the same DNAmicroarray platform. These PCR-microarray LOCs combine
the advantage ofmicroﬂuidics with the opportunity to perform a fast and
small volume low-density multigenic analysis (hybridization and detec-
tion), on the same device. The development of these technologies has
reached such a level that enables the production of diagnostic tests,
enabling the detection of several infectious disease (such as viral
inﬂuenza, sexually transmitted diseases, and poverty related disease),
pharmacogenomics and genotyping (such as SNP) analysis [40,44,46].
In the next sections, we will discuss one hybrid and three integrated
PCR-microarray platforms.
5.1.1. INFINITY System
An example of a hybrid (not integrated) platform is the INFINITY Sys-
tem by AutoGenomics [47–49]. This platform associates a multiplex PCR
with automatedmicroarray hybridization, by using BioFilmChipmicroar-
rays that can be conﬁgured with hundreds of biomarkers. Labeling, hy-
bridization, scanning and data analysis steps have been automated and
are performed within the Inﬁnity Analyzer, whereas sample extraction,
puriﬁcation and PCR ampliﬁcation are performed separately using re-
agents and instrumentation provided by the same company. Although
hybrid, this platform is versatile enough to allow diagnostic tests for a
wide range of disease signatures in the areas of women's health, cancer,
viral inﬂuenza, as well as pharmacogenomics. Some of these tests are al-
ready FDA cleared and CEmarkedwhile others are under review [47,48].
5.1.2. Rheonix CARD
The Rheonix CARD platform by REONIX is a fully automated
microﬂuidic platform based on disposable plastic cards [44,50]. The
laminated polystyrene Rheonix CARD is a cartridge that is able tomanipulate reagents internally, with its active ﬂuidic network of
pumps, valves and channels. The Rheonix CARD is inserted onto
the Rheonix EncompassMDx instrument that includes: liquid han-
dler, thermal cycler, hybridization heaters, barcode reader, imager
and PC. For each assay, the phases of cell lysis, nucleic acid puriﬁca-
tion, multiplex PCR, labeling, hybridization and microarray detec-
tion are performed under software control, producing a sample-to-
result LOC. Only one step requires the operator presence: the initial
introduction of untreated specimens directly onto the disposable
card. Rheonix CARD assays for different clinical purposes (from in-
fectious disease to pharmacogenomics) have been developed but
are not yet cleared by the FDA [48,50].
5.1.3. Verigene System
The Verigene System by Nanosphere is an automated platform
based on disposable test cartridges. The platform consists of two
modules, the Verigene Processor (fully automated) and the Verigene
Reader, which are able to drive the different experimental phases on
the multi-chambered ﬂuidic cartridges. When an untreated speci-
men is loaded onto the cartridge by the user, it undergoes to nucleic
acid extraction and puriﬁcation (with magnetic microparticles), PCR
ampliﬁcation (optional), hybridization and washing within the
Verigene processing unit [51]. In particular, the array hybridization
is carried out using nanoparticle-conjugated oligonucleotides
(~200) of Nanosphere's property (Gold nanoparticles hybridization
technology) [52]. After hybridization, the cartridge is removed
from the processor unit and only the microarray glass slide is
inserted into the Verigene Reader, where signals are detected and
analyzed [51]. Verigene tests have been approved by the FDA for dif-
ferent purposes of clinical relevance [51,53–55].
5.1.4. In-Check Lab-on-Chip
STMicroelectronics has developed the In-Check Lab-on-Chipplatform
for fast, automated and qualitative nucleic acid analysis (shown in Fig. 1,
panels a–e) [45,56–58]. This platform is made up of a silicon-based LOC,
an independent modular Temperature Control System (TCS) to control
thermal process, an Optical Reader (OR) to acquire ﬂuorescence micro-
array signals and software for image analysis. The silicon chip integrates
microﬂuidic handling, a miniaturized multiplex PCR chamber and a
low-densitymicroarray, containing up to 400 spots [59]. Themicroarray
and PCRmodules are ﬂuidically connected and are both thermally driv-
en by a TCS module. After hybridization, the microarray is read by the
OR in a few seconds. This product is in continuous development and
has been recently implemented with nucleic acids extraction methods,
in order to obtain a fully integrated system sample-to-result [60]. Its ap-
plication to diagnostics has already begunwith the customization of in-
fectious diseases tests that are cleared for in vitro diagnostics [46].
5.2. PCR andmicroarray integration: an opportunity for real-time detection
More than ﬁfteen years ago, we witnessed the transition from end-
point to real-time detection PCR [61]. In the real-time PCR conﬁguration,
the ﬂuorescence emission is measured during the exponential growth
phase where increase of ﬂuorescent signal is directly proportional to
the number of amplicons generated. Another improvement of real-time
PCR conﬁguration was the wide dynamic range of detection of starting
target molecules, which increases up to eight orders of magnitude com-
pared with traditional PCR. Thanks to these advantages, the real-time
PCR has easily moved to clinical practice, allowing tests for a wide range
of applications, from SNPs detection to copy number variations [62,63].
In a traditional DNA microarray experiment, the measurement of
ﬂuorescence levels is performed when the equilibrium phase of hybrid-
ization is reached. This steady-state phase produces a limited dynamic
range of detection. The tremendous technological advances in LOC de-
vices are now offering the opportunity for a real-time conﬁguration of
DNA microarrays [64–67]. Their ability to acquire signals in real-time
Fig. 1.Real-time detection on the In-Check LOCplatform. (A) Silicon based devicemounted on a 1× 3printed circuit board (PCB) support. (B) Sample loading phase on biochipholding by a
clamp support. (C) Fluorescence detection phase byusing anOptical Reading system. (D)A cross section of theplatformhighlighting themain internal units of the silicon biochip and those
of the OR system. (E) Diagram showing the In-Check platform real-time workﬂow. (F) Hybridization kinetic— SYBR Green ﬂuorescence signal at different hybridization times. The graph
shows how hybridization reaches the steady-state level in a few seconds. (G) Microarray images of the same spot at three different hybridization temperatures (in °C). (H)Melting curve
showing ﬂuorescence as function of temperature. The curve shows a peak at 56 °C corresponding to the melting temperature of the hybridization products.
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ity to perform absolute quantiﬁcation of amplicons cycle by cycle. In a
real-time conﬁguration, the kinetics of hybridization can also be moni-
tored and used to distinguish speciﬁc from aspeciﬁc products and re-
duce the time of execution of the test.
In Fig. 1 (panels d–h) we show an example of real-time microarray
detection performed on the In Check Lab-on-Chip platform. The hybrid-
ization level was detected by the OR system using SYBR Green, a mole-
cule that emits ﬂuorescence when it binds to double-stranded DNA. As
shown in the hybridization curve obtained (h), the hybridization pro-
cess takes only a few seconds and can be monitored step by step. The
readout is instantaneous as opposed to the off-line time-consuming
scanning procedure that requires both lengthy hybridization and
washing-steps. Finally, by performing a melting curve (panels g, h) it
is possible to control the speciﬁcity of hybridization signals. The
presence of a mismatch would produce a shifted melting curve.
Thanks to LOCs miniaturization, PCR-Microarray integration and
real-time detection, it is now possible to control the rapid process of hy-
bridization and increase the accuracy and reproducibility of microarray
technology.
6. Conclusion
The genomic approach is opening new horizons in understanding
diseases, leading to the development of new diagnostic tools, but their
translation to clinical practice is still at the beginning. As detailed in
this review, a real progress may soon be reached with the advent ofPCR-microarray platforms combining multigenic analysis with real-
time detection. Their sample-to-result characteristic and simple use
will enable them to bridge the technical gap between research and
clinics. The miniaturization, integration and automation of these tools
increase accuracy and reproducibility, making them more suitable for
routine use. With these advances, genome-based tests have the poten-
tial to become a standard tool for mainstream diagnostics, in order to
monitor disease onset and progression, facilitate individualized patient
therapy and, ultimately, improve patient outcomes.
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